Active substance
Results for the substance tivozanib
2 results
About this active substance
Tivozanib is a tyrosine kinase inhibitor used for the treatment of advanced renal cell carcinoma. It works by blocking vascular endothelial growth factor receptors (VEGFR), thereby reducing the formation of new blood vessels that supply tumors.
The medication is taken orally, usually once daily, as directed by a doctor. The treatment is primarily used in patients who have not responded to other therapies or who require a second-line option.
Patients should be monitored for potential side effects, such as high blood pressure, diarrhea, or fatigue. It is important for patients to inform their doctor of any unusual symptoms.
Common side effects include high blood pressure, fatigue, diarrhea, and decreased appetite. In rare cases, severe reactions such as heart failure or thromboembolic events may occur. Patients should be informed of these risks before starting treatment.
The medication is taken orally, usually once daily, as directed by a doctor. The treatment is primarily used in patients who have not responded to other therapies or who require a second-line option.
Patients should be monitored for potential side effects, such as high blood pressure, diarrhea, or fatigue. It is important for patients to inform their doctor of any unusual symptoms.
Common side effects include high blood pressure, fatigue, diarrhea, and decreased appetite. In rare cases, severe reactions such as heart failure or thromboembolic events may occur. Patients should be informed of these risks before starting treatment.